Discontinued — last reported Q3 '23
Edwards Lifesciences Income taxes receivable increased by 27.1% to $400.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 34.4%, from $297.80M to $400.10M.
An increase suggests the firm is owed money by tax authorities, which can be a temporary liquidity benefit or a sign of tax overpayment.
This represents the amount of income tax paid to tax authorities that exceeds the actual tax liability for the period, r...
Standard tax asset found on the balance sheets of most large, multi-jurisdictional corporations.
other_income_tax_receivable| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $286.40M | $290.00M | $293.70M | $293.90M | $297.80M | $297.80M | $303.90M | $314.80M | $400.10M |
| QoQ Change | — | — | +1.3% | +1.3% | +0.1% | +1.3% | +0.0% | +2.0% | +3.6% | +27.1% |
| YoY Change | — | — | — | — | — | +4.0% | +2.7% | +3.5% | +7.1% | +34.4% |